Technology Networks recently spoke with Ofer Sharon, CEO of OncoHost, to learn more about ways to overcome patient resistance to immunotherapy and how proteomic profiling in oncology can aid diagnosis, prognosis and treatment of this incredibly complex disease.

Technology Networks spoke to Michael Feldschuh, CEO, Daxor, to learn more about the importance of maintaining optimal blood volume, how the BVA-100 test can help to measure this, and how clinicians can use the information it provides to guide treatment of COVID-19 patients.

Targeted proteomics start-up ProteiQ Biosciences recently announced the launch of InfineQ, its cloud-based solution software for near real-time processing of proteomics data. Technology Networks spoke with Arnoud Groen, CSO and co-founder of ProteiQ, to learn more about the solution and how it provides the scale and speed required for biomarker discovery.

Lab efficiency is critical to speeding up development processes, yet many researchers find they spend more time managing consumables data than working at the bench. Lab informatics is one solution to this problem.

Technology Networks spoke with Amelie Boulais, Vaccine Marketing Manager, Sartorius, to find out more about how Sartorius is supporting vaccine development at this critical time and the power of collaboration.

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Technology Networks spoke with Yossi Pollak, CEO, Sight Diagnostics, to learn more about OLO and how it is being used to minimize the challenges of handling and analyzing blood samples from COVID-19 infected patients.

CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.

Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.

What barriers still exist to the full implementation of next-generation sequencing (NGS) in the diagnostics space, and how can we remove them? Technology Networks recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific, to learn more.